Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Quick facts
Marketed products
- zidovudine + lamivudine + efavirenz · Infectious Disease / Virology
This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing the virus from copying its genetic material and integrating into host cells. - zidovudine+lamivudine+lopinavir/ritonavir · Infectious Disease / Virology
This combination inhibits HIV replication by blocking reverse transcriptase (zidovudine and lamivudine) and protease (lopinavir/ritonavir) enzymes required for viral reproduction.
Phase 3 pipeline
- Placebo (for Bezafibrate) · Cardiovascular
Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran portfolio CI brief
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran pipeline updates RSS
Frequently asked questions about Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
What are Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran's marketed drugs?
Top marketed products include zidovudine + lamivudine + efavirenz, zidovudine+lamivudine+lopinavir/ritonavir.
What is Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran's pipeline?
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Placebo (for Bezafibrate).
Related
- zidovudine + lamivudine + efavirenz · Infectious Disease / Virology
- zidovudine+lamivudine+lopinavir/ritonavir · Infectious Disease / Virology
- Sector hub: All tracked pharma companies